IPX · IperionX Limited

Current Thesis

IperionX is a US critical-minerals sovereignty story domestic titanium metal plus a Tennessee heavy-rare-earth resource whose marquee catalyst has now fired and been rejected by the tape. The Titan Definitive Feasibility Study landed 2026-06-04 (US$813M after-tax NPV8, 39.4% IRR, US$1.9B after-tax FCF, ~US$2.8B LOM EBITDA, 3.6-yr payback, heavy-REE concentrate of Dy/Tb/Y) and the stock fell instead of broke out: -10.3% on the ASX on 2026-06-04, then -12.58% on the NASDAQ ADR to a $35.22 close on 2026-06-05 a ~22% two-session unwind off the event the prior leg had been pricing. The heavy-REE-sovereignty narrative (China Dy/Tb chokepoint, Pentagon-funded domestic supply) is intact, but the momentum leg that carried the stock into the DFS has broken. The current state is a digestion tape, not an accelerating one.

Bull Case

• Titan DFS economics, 2026-06-04: US$813M after-tax NPV8, 39.4% IRR, US$1.9B after-tax FCF, ~US$2.8B LOM EBITDA over a 14-year mine plan fully covered by Proved & Probable reserves; total development capital US$381.3M; 3.6-yr payback. A domestic source of dysprosium, terbium and yttrium the precise metals China restricts.
• Government de-risking supply: EXIM approved an US$11M loan on 2026-03-31 for the Virginia titanium campus, stacking on the US$99M SBIR Phase III IDIQ and US$47.1M IBAS award (final US$4.6M obligated 2026-01-16) plus 290 t of free Ti-64 scrap feedstock.
• Macro backstop precedent is live: MP Materials' 2026 DoD public-private partnership set a US$110/kg NdPr price floor and a government equity stake; a US$2.5B Strategic Resilience Reserve bill was introduced January 2026; the DoD is soliciting supply across 13 critical minerals against a 2027 defense deadline. Titan's Dy/Tb concentrate is a candidate for the same template an offtake, price-floor or equity event would re-rate the equity.
• Sell-side raising into the weakness: BTIG reiterated Buy and lifted its target to $55 on 2026-06-05; consensus sits ~$55–57 (median ~$53), 5 buy / 0 sell, against a $35.22 spot the street has not followed price down.
• Production ramping: HAMR titanium powder running 24/7 since Q1 2026 (~50 tpa annualized in March), the 2026-05-21 SACMI 300-ton press commissioned (up to ~11M parts/yr), targeting ~200 tpa run-rate by end-CY2026 and 1,400 tpa by mid-2027.

Bear Case

• The catalyst is spent and the tape rejected it: the DFS the prior advance was pricing is out, and price fell ~22% across 2026-06-04/05. That buy-the-rumour unwind leaves no scheduled near-term catalyst until the late-July cash report.
• management guides 2026-06-30 cash to US$36–40M. At that pace a capital raise in H2 2026 is a when-not-if, and dilution is the dominant overhang.
• Open securities-fraud probe: on 2026-03-13 IPX restated Right-of-use assets from $21,445,038 to $3,752,600 ("typographic error"); the ADR fell 27.4% to $29.44 by 2026-03-16. Frank R. Cruz and Howard G. Smith are investigating; an SEC inquiry or class action reopens that wound.
• Structure has rolled: the $35.22 close gave back the entire post-Army-validation advance and lost the $36 shelf that defined the recovery. Failing the breakout level on the marquee catalyst is distribution behaviour, and the advance into the DFS has fully unwound.
• Years to cash flow: the DFS is a study, not a financed mine; Titan needs project finance plus construction, and the 1,400 tpa titanium line is mid-2027. The equity funds years of capex ahead of free cash flow.

Setup & Price Structure

• Spot $35.22 (2026-06-05 close), after-hours $35.71; market cap ~US$1.30B.
• 52-week range $21.66–$61.45: spot is ~43% below the high and ~+20% above the 2026-03-16 crash low of $29.44 the middle of the recovery range, no longer pressing the highs.
• Two-day reversal sequence: -10.3% ASX (2026-06-04) → -12.58% NASDAQ (2026-06-05). The DFS produced a bearish outside-day reversal on heavy volume.
• The $36 level that the prior leg held as support is lost on a daily-close basis. Next structural reference below is the $33 March-recovery base; under that, the $29.44 low. Overhead, reclaiming the ~$40–42 pre-DFS shelf on volume is the precondition for any momentum re-engagement.
• Theme state: MATURING / digesting. The anticipation phase peaked into the DFS; absent a new catalyst the path of least resistance is sideways-to-lower while the raise overhang sits.

Catalyst Calendar (next 30 days)

• 2026-06-09 (unverified): US data vendors flag an "earnings date." IperionX is ASX-listed with a June 30 fiscal year and reports cash via Appendix 4C with no EPS print treat this as a likely vendor artifact; no confirmed binary print is scheduled. Worth watching only for any unscheduled filing.
• ~late July 2026 (est.): June-quarter Appendix 4C cash-flow report the real liquidity read. Confirms the 2026-06-30 US$36–40M cash guide and the timing/size of any raise. This cash report is the genuine binary for the name.
• Open-ended, next 30d: any DoD / EXIM / DPA Title III offtake, price-floor or equity announcement on Titan's heavy-REE concentrate the MP-Materials-style event that would re-accelerate the narrative. No confirmed date; a watch item.
• Open-ended: any escalation of the Frank R. Cruz / Howard G. Smith securities investigation (SEC inquiry, class-action filing).

What Would Change Our Mind

• Re-engage long on a higher-low base that reclaims the ~$40–42 pre-DFS shelf on above-average volume, or on a confirmed DoD/government REE offtake, price-floor or equity event for Titan.
• Thesis breaks on a weekly close below $33 (loses the March-recovery base built off the $29.44 low), confirming the recovery structure has failed and the name steps aside.
• Hard invalidation on an equity raise priced more than 10% below spot (dilution at a discount), or any SEC/class-action escalation of the securities probe.
• Conviction returns if the late-July Appendix 4C shows cash at or above the top of the US$36–40M guide with a funded path strategic or government capital rather than discounted equity removing the dilution overhang.

Correlation Notes

• Trades with the US critical-minerals / rare-earth sovereignty basket MP (MP Materials) and other Dy/Tb-exposed names which moves on China export-control headlines and DoD funding announcements rather than broad equity beta.
• The titanium side correlates with defense-industrial demand (DoD primes, additive-manufacturing supply chains) and aerospace fastener-qualification news.
• Dual-listed: ASX IPX.AX prints first; the NASDAQ ADR (IPX) gaps overnight to the Australian session, so single-day ADR moves can compound the prior ASX session the 2026-06-04/05 sequence is that pattern.
• Sensitive to the broader REE price complex and to government price-floor policy; the US$110/kg NdPr floor set for MP is the reference point the market extrapolates to any new domestic entrant.